95 related articles for article (PubMed ID: 19861688)
1. P-REX2a driving tumorigenesis by PTEN inhibition.
Leslie NR
Sci Signal; 2009 Oct; 2(94):pe68. PubMed ID: 19861688
[TBL] [Abstract][Full Text] [Related]
2. Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a.
Fine B; Hodakoski C; Koujak S; Su T; Saal LH; Maurer M; Hopkins B; Keniry M; Sulis ML; Mense S; Hibshoosh H; Parsons R
Science; 2009 Sep; 325(5945):1261-5. PubMed ID: 19729658
[TBL] [Abstract][Full Text] [Related]
3. Regulation of PTEN inhibition by the pleckstrin homology domain of P-REX2 during insulin signaling and glucose homeostasis.
Hodakoski C; Hopkins BD; Barrows D; Mense SM; Keniry M; Anderson KE; Kern PA; Hawkins PT; Stephens LR; Parsons R
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):155-60. PubMed ID: 24367090
[TBL] [Abstract][Full Text] [Related]
4. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.
Cully M; You H; Levine AJ; Mak TW
Nat Rev Cancer; 2006 Mar; 6(3):184-92. PubMed ID: 16453012
[TBL] [Abstract][Full Text] [Related]
5. Interference of P-REX2a may inhibit proliferation and reverse the resistance of SGC7901 cells to doxorubicin.
Ai Y; Zhou Q; Li L; Pan Z; Guo M; Han J
Oncol Lett; 2018 Mar; 15(3):3185-3191. PubMed ID: 29435055
[TBL] [Abstract][Full Text] [Related]
6. PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting.
Ciuffreda L; Falcone I; Incani UC; Del Curatolo A; Conciatori F; Matteoni S; Vari S; Vaccaro V; Cognetti F; Milella M
Adv Biol Regul; 2014 Sep; 56():66-80. PubMed ID: 25088603
[TBL] [Abstract][Full Text] [Related]
7. CELF2 suppresses non-small cell lung carcinoma growth by inhibiting the PREX2-PTEN interaction.
Yeung YT; Fan S; Lu B; Yin S; Yang S; Nie W; Wang M; Zhou L; Li T; Li X; Bode AM; Dong Z
Carcinogenesis; 2020 May; 41(3):377-389. PubMed ID: 31241130
[TBL] [Abstract][Full Text] [Related]
8. PTEN mutation: many birds with one stone in tumorigenesis.
Liu W; Zhou Y; Reske SN; Shen C
Anticancer Res; 2008; 28(6A):3613-9. PubMed ID: 19189642
[TBL] [Abstract][Full Text] [Related]
9. Nuclear phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3-kinase, Akt, and PTen: emerging key regulators of anti-apoptotic signaling and carcinogenesis.
Martelli AM; Cocco L; Capitani S; Miscia S; Papa S; Manzoli FA
Eur J Histochem; 2007; 51 Suppl 1():125-31. PubMed ID: 17703603
[TBL] [Abstract][Full Text] [Related]
10. Phosphatase and tensin homologue deleted on chromosome 10: extending its PTENtacles.
Stiles BL
Int J Biochem Cell Biol; 2009 Apr; 41(4):757-61. PubMed ID: 18950730
[TBL] [Abstract][Full Text] [Related]
11. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
12. PTEN, more than the AKT pathway.
Blanco-Aparicio C; Renner O; Leal JF; Carnero A
Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
[TBL] [Abstract][Full Text] [Related]
13. Regulation of phosphoinositide metabolism, Akt phosphorylation, and glucose transport by PTEN (phosphatase and tensin homolog deleted on chromosome 10) in 3T3-L1 adipocytes.
Ono H; Katagiri H; Funaki M; Anai M; Inukai K; Fukushima Y; Sakoda H; Ogihara T; Onishi Y; Fujishiro M; Kikuchi M; Oka Y; Asano T
Mol Endocrinol; 2001 Aug; 15(8):1411-22. PubMed ID: 11463863
[TBL] [Abstract][Full Text] [Related]
14. Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
Choi HJ; Chung TW; Kang SK; Lee YC; Ko JH; Kim JG; Kim CH
Glycobiology; 2006 Jul; 16(7):573-83. PubMed ID: 16574813
[TBL] [Abstract][Full Text] [Related]
15. PTEN and the PI3-kinase pathway in cancer.
Chalhoub N; Baker SJ
Annu Rev Pathol; 2009; 4():127-50. PubMed ID: 18767981
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase.
Leslie NR; Gray A; Pass I; Orchiston EA; Downes CP
Biochem J; 2000 Mar; 346 Pt 3(Pt 3):827-33. PubMed ID: 10698713
[TBL] [Abstract][Full Text] [Related]
17. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
18. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.
Steelman LS; Abrams SL; Whelan J; Bertrand FE; Ludwig DE; Bäsecke J; Libra M; Stivala F; Milella M; Tafuri A; Lunghi P; Bonati A; Martelli AM; McCubrey JA
Leukemia; 2008 Apr; 22(4):686-707. PubMed ID: 18337767
[TBL] [Abstract][Full Text] [Related]
19. Metabolic switching of PI3K-dependent lipid signals.
Downes CP; Leslie NR; Batty IH; van der Kaay J
Biochem Soc Trans; 2007 Apr; 35(Pt 2):188-92. PubMed ID: 17371235
[TBL] [Abstract][Full Text] [Related]
20. Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity.
Hjelmeland AB; Hjelmeland MD; Shi Q; Hart JL; Bigner DD; Wang XF; Kontos CD; Rich JN
Cancer Res; 2005 Dec; 65(24):11276-81. PubMed ID: 16357132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
